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Patients with end-stage renal disease (ESRD) undergoing haemodialysis (HD) experience oxidative/carbonyl stress, which is
postulated to increase after the HD session. The inﬂuence of diabetes mellitus and sex on oxidation of plasma proteins in ESRD
has not yet been clariﬁed despite that diabetic nephropathy is the most common cause of ESRD in developed and developing
countries and despite the increasingly emerging diﬀerences between males and females in epidemiology, pathophysiology,
clinical manifestations, and outcomes for several diseases. Therefore, this study aimed to evaluate the possible eﬀect of type 2
diabetes mellitus, gender, and dialysis ﬁlter on plasma level of protein carbonyls (PCO) in ESRD patients at the beginning and
at the end of a single HD session. Results show that mean post-HD plasma PCO levels are signiﬁcantly higher than mean pre-
HD plasma PCO levels and that the type of dialysis ﬁlter and dialysis technique are unrelated to plasma PCO levels. The mean
level of plasma PCO after a HD session increases slightly but signiﬁcantly in nondiabetic ESRD patients compared to diabetic
ones, whereas it increases more markedly in women than in men. These novel ﬁndings suggest that women with ESRD are
more susceptible than men to oxidative/carbonyl stress induced by HD.
1. Introduction
Compared to the general population, patients with chronic
kidney disease (CKD) are at higher risk for cardiovascular
disease (CVD) because of higher prevalence of traditional
(such as diabetes mellitus, left ventricular hypertrophy, dysli-
pidaemia, hypertension, and obesity) and nontraditional car-
diovascular risk factors. The latter include uraemia, anaemia,
inﬂammation, and oxidative stress, which all together form
part of the malnutrition-inﬂammation complex (or cachexia)
syndrome, which is a strong predictor of morbidity and mor-
tality in these patients. [1–7]. The subgroup of CKD patients
that undoubtedly experience the highest degree of oxidative
stress is constituted by those patients with end-stage renal
disease (ESRD) undergoing haemodialysis (HD). Oxidative
stress in ESRD derives from both enhanced oxidative
capacity, which is at least partly due to systemic (micro)-
inﬂammation and upregulation of superoxide-producing
enzymes [5, 8] and diminished antioxidant defences, the lat-
ter including impaired enzyme activities and decreased levels
of antioxidant vitamins C and E [5, 8–10]. Depletion of circu-
lating antioxidant vitamins in ESRD may originate from diet
restriction, reduced absorption, uraemia-related alterations
of metabolic pathways, and intradialytic losses [10].
In haemodialysed patients, oxidative stress, which may
act synergistically with inﬂammation, is involved in the
development of long-term complications such as amyloid-
osis, atherosclerosis, and CVD [1, 3, 11]. Plasma biomarkers
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of protein oxidation in ESRD patients on maintenance HD
were measured as indicator of oxidative stress in several stud-
ies. Plasma protein oxidation is highlighted by decreased pro-
tein thiols [12, 13], which might result from the formation of
mixed disulphides between protein thiols and low molecular
mass aminothiols (S-thiolation). S-thiolated plasma proteins,
measured as protein thiolation index (PTI) [14], are indeed
increased in ESRD patients on maintenance HD [12, 13].
Other biomarkers of protein oxidation in haemodialysed
patients are plasma protein-bound dityrosines [15, 16] as
well as plasma protein carbonyls (PCO), whose levels are ele-
vated compared to healthy subjects [17–19]. Similarly, bio-
markers of inﬂammation are elevated in haemodialysed
patients [20–22].
While it appears that oxidative stress in haemodialysed
patients may result from uraemia per se [1, 23], the HD pro-
cedure itself may contribute to oxidative/carbonyl stress.
Indeed, a few studies showed that plasma PCO levels were
signiﬁcantly higher at the end of a single HD session than
before it [17–19, 24, 25]. A prospective cohort study demon-
strated that initiation of maintenance HD procedure does not
have signiﬁcant inﬂuence on serum levels of the inﬂamma-
tion biomarkers, C-reactive protein, interleukin-6, and inter-
leukin-10, as well as plasma PCO [26]. Otherwise, levels of
pentraxin-3, an inﬂammation biomarker belonging to the
same protein family of C-reactive protein (pentraxins),
which is rapidly produced locally to the site of inﬂammation
by several cell types and released by neutrophils upon stimu-
lation, were signiﬁcantly increased at the end of the HD ses-
sion [22]. This ﬁnding suggests that the HD procedure is an
exacerbating factor for both oxidative/carbonyl stress and
inﬂammation, presumably due to the activation of neutro-
phils upon contact with the dialysis ﬁlter [11]. Hence, it is
postulated that oxidative/carbonyl stress increases in ESRD
patients after the HD session.
Only a few studies have focused speciﬁcally on the impact
of a single HD session on plasma PCO levels in ESRD
patients [17–19, 24, 25]. Moreover, the relative importance
of diabetes mellitus and sex on plasma PCO levels in haemo-
dialysed patients remains poorly deﬁned and with conﬂicting
results [26–28]. This despite that diabetic nephropathy, alone
or in combination with hypertensive nephropathy, is the
most common cause of ESRD in developed and developing
countries and despite the increasingly emerging diﬀerences
between male and female in epidemiology, pathophysiology,
clinical manifestations, and outcomes for several diseases,
among which those displaying oxidative stress-mediated
inﬂammation, such as CVD [29–31]. However, whether sex
diﬀerences exist with respect to biomarkers of oxidative
stress before and after a single HD session in ESRD patients
is largely unknown. Therefore, we determined the plasma
PCO levels in each individual HD patient before and after
a single HD session. This was done by dividing the HD
population into groups based on the cooccurrence of type 2
(non-insulin-dependent) diabetes mellitus and the gender.
Moreover, the HD population was divided into groups also
based on the dialysis ﬁlter used, in order to ascertain eventual
diﬀerences attributable to ﬁlter characteristics and, therefore,
to the diﬀerent HD techniques. In fact, there is some evidence
indicating that techniques that combine diﬀusion and
convection, such as online haemodiaﬁltration, may reduce
oxidative stress improving the haemodynamic tolerance
and the clearance of uremic toxins [32, 33]. However, the
eﬀect of convective transport on oxidative stress needs a
stronger conﬁrmation.
2. Materials and Methods
2.1. Study Design and Participants. The study was approved
by the institutional review board before initiation and carried
out according to the Code of Ethics of the World Medical
Association (Declaration of Helsinki). All the 69 Caucasian
patients enrolled in the study belong to stage 5 of CKD and
are referred to as ESRD patients on maintenance HD. In
addition to HD, patients are treated with a pharmacological
treatment that varies upon the clinical necessities and con-
sists mainly on the treatment of ESRD complications. Most
of the patients assume drugs for anaemia (i.e., iron intrave-
nous supplementation and/or erythropoietin) and bone
mineral disorder (i.e., calcium supplementation, phosphate
binders, vitamin D, paricalcitol, and/or calcimimetics). In
addition, patients may also take speciﬁc drugs for other
comorbidities, for example, hypertension, diabetes mellitus,
ischemic cardiopathy, and other vasculopathies. Blood sam-
ples were collected, after informed written consent, from
ESRD patients undergoing maintenance HD at the Nephrol-
ogy and Dialysis Unit of the Humanitas Clinical and
Research Center (Rozzano, Milan, Italy). The samples were
collected at the arterial line at the beginning and at the end
of the HD session. The presence of a clinically overt infec-
tious process was the only exclusion criteria. For every
patient, an anamnestic record was collected. A deidentiﬁca-
tion of the samples was performed before any additional data
processing. The baseline clinical characteristics of recruited
patients are shown in Table 1. Control blood samples were
collected from 20 (10 males and 10 females) age-matched
voluntary healthy donors at the Analysis Laboratory of
the University of Milan (Laboratorio Analisi, Università
degli Studi di Milano) after obtaining informed verbal con-
sent. Criteria included no known history of CKD or other
diseases that could inﬂuence the analysis. In particular,
healthy subjects were tested for serum creatinine in order to
exclude CKD.
2.2. Dialysis Filters. We used diﬀerent dialysis ﬁlters, all
characterised by high-ﬂux (deﬁned as a β2-microglobulin
clearance of over 20ml/min) synthetic biocompatible mem-
branes. In particular, the ﬁlters used are the following, classi-
ﬁed by the dialysis technique:
(1) Diﬀusive technique (standard bicarbonate haemo-
dialysis) (n = 41)
(a) Revaclear™ 300, whose membrane is made of
polyarylethersulphone (PAES) + polyvinylpyrro-
lidone (PVP) (surface: 1.4m2, thickness: 35 μm),
for 23 patients
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(b) Revaclear™ 400, whose membrane is made of
PAES+PVP (surface: 1.8m2, thickness: 35 μm),
for 14 patients
(c) Filtryzer® 1.6, whose membrane is made of poly-
methyl metacrylate (PMMA) (surface: 1.6m2,
thickness: 30 μm), for 4 patients
(2) Diﬀusive plus convective techniques (online haemo-
diaﬁltration (online HDF) and acetate-free bioﬁltra-
tion (AFB)) (n = 27)
(a) Polyﬂux™ 170 H, whose membrane is made of
PAES+PVP+polyamide (PA) (surface: 1.7m2,
thickness: 50 μm), for 14 patients
(b) Polyﬂux™ 210 H, whose membrane is made of
PAES+PVP+PA (surface: 2.1m2, thickness:
50 μm), for 11 patients
(c) Nephral™ ST 400, whose membrane is made
of acrylonitrile/methallyl sulphonate copolymer,
coated with high-molecular-weight polyethyle-
neimine (PEI) (surface: 1.65m2, thickness:
42 μm), for one patient
(d) Nephral™ ST 500, whose membrane is made of
acrylonitrile/methallyl sulphonate copolymer,
coated with PEI (surface: 2.15m2, thickness:
42 μm), for one patient
Filters a, b, and d–g are produced by Gambro®-Baxter,
whereas ﬁlter c is produced by Toray Industries Inc.
2.3. Sample Collection. Venous blood samples of 10ml were
collected from ESRD patients before HD session, and 5ml
were obtained after the same session. All samples were col-
lected on the long interdialytic interval, that is, two days apart
from the previous HD session. Blood was taken from the
arteriovenous ﬁstula or central venous catheter. K3EDTA
was used as anticoagulant in all the blood samples. From
healthy donors, 10ml of venous blood was collected from
the antecubital vein. All the samples were processed within
the ﬁrst hour from blood sampling through centrifugation
for 10min at 1000g, obtaining pre-HD and post-HD plasma
aliquots from ESRD patients and plasma aliquots from
healthy subjects. Such aliquots were stored at −80°C until
the execution of the assays.
2.4. Detection of Plasma Protein Carbonylation by SDS-PAGE
and Western Blot. Plasma proteins were fractionated on
12.5% (w/v) reducing SDS-PAGE gels and electroblotted
onto a polyvinylidene diﬂuoride (PVDF) membrane. Protein
carbonylation was detected, after derivatization with DNPH,
with anti-DNP antibodies speciﬁc for the 2,4-dinitrophenyl
hydrazone-carbonyl adduct by Western blot immunoassay
as previously reported [34, 35]. Immunoreactive protein
bands were visualized by enhanced chemiluminescence
(ECL). Protein bands on PVDFmembranes were then visual-
ized by washing the blots extensively in PBS and then stain-
ing with Ponceau Red.
2.5. Determination of Plasma Protein Carbonyls by Enzyme-
Linked Immunosorbent Assay (ELISA). Plasma PCO were
measured using the ELISA kit manufactured by Enzo Life
Sciences (ALX-850-312-KI01). Carbonylated protein stan-
dard (40mg/ml containing 0-0.12-0.22-0.42-0.7-0.9 nmol
carbonyls/mg protein) and human plasma samples (60–
75mg/ml) were diluted 1 : 40 in DNPH solution and incu-
bated 45min to allow PCO derivatization. A 1 : 200 dilution
in ELISA buﬀer was then performed before adding 200μL
(1-2μg of protein) in each ELISA plate well. We incubated
ELISA plate overnight at 4°C to allow protein binding. ELISA
assay was performed according to the manufacturer’s
instructions. Absorbance of plate wells was read at 450nm
using the Plate Reader TECAN Inﬁnite® 200 PRO. In all
the performed assays, calibration line showed an R2 close to
0.99. We then calculated carbonyl content of samples by
using the regression factors (intercept with the y-axis and line
slope) obtained from standard curve.
2.6. Determination of Clinical Laboratory Parameters. Creat-
inine, C-reactive protein, white blood cell count, albumin,
ﬁbrinogen, haemoglobin, ferritin, total iron-binding capac-
ity, urea, sodium, potassium, calcium, and phosphorus were
measured by standardized methods at the clinical laboratory
of the Humanitas Clinical and Research Center [12, 16].
2.7. Statistical Analysis. The paired Student’s t-test was used
to test whether diﬀerences in plasma PCO level in ESRD
patients before (pre-HD) and after (post-HD) a single HD
session were signiﬁcant. The paired Student’s t-test was also
used to test for diﬀerences in plasma PCO levels before and
after a single HD session by dividing the haemodialysed
Table 1: Characteristics of haemodialysed patients with ESRD.
Data are expressed as mean ± standard deviation.
Haemodialysed patients
(n = 69)
Reference
range
Age (years) 69.0± 1.5 —
Dialysis vintage
(years)
5.8± 0.46 —
Sex 45 male, 24 female —
Diabetes mellitus
47 nondiabetic,
22 diabetic
—
Creatinine (mg/dl) 9.24± 0.35 0.6–1.3
Urea (mg/dl) 148.98± 4.55 10.00–50.00
C-reactive protein
(mg/dl)
0.55± 0.08 0.01–1
Albumin (g/dl) 3.5± 0.04 3.5–5
White blood cells
(cells/mm3)
7257.97± 271.06 4 · 103
Haemoglobin (g/dl) 11.03± 0.12 13–18
Sodium (mmol/l) 137.80± 0.38 135–145
Potassium (mmol/l) 5.26± 0.09 3.5–5.1
Calcium (mmol/l) 2.22± 0.02 2.1-2.6
Phosphorus (mmol/l) 1.63± 0.05 0.8–1.5
Ferritin (ng/ml) 201.26± 16.85 20–250
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patients depending on the dialysis ﬁlter used, the cooccur-
rence of type 2 diabetes mellitus, and the gender. All the
values are expressed as mean and standard errors (SE).
A p value <0.05 was considered to be signiﬁcant. The statisti-
cal signiﬁcances are marked as ∗ = p < 0 05 and ∗∗ = p < 0 01.
The relationship between pre-HD and post-HD PCO levels
was investigated by simple linear regression analysis.
3. Results
PCO are considered the most general and the most com-
monly used biomarkers of severe oxidative protein damage.
The results of protein carbonylation assessed by Western
blotting using anti-DNP antibodies from ﬁve ESRD patients
and ﬁve age-matched voluntary healthy donors are pre-
sented in Figure 1. Plasma proteins from healthy subjects
showed a very low level of carbonyl content (Figure 1(b)),
whereas plasma proteins from ESRD patients clearly exhib-
ited an increase in carbonyl content (Figure 1(e)). We applied
reversible Ponceau Red staining to assess equal loading of
gels (Figures 1(c) and 1(f)).
We also determined the eﬀect of HD on the plasma PCO
levels, measured by a sensitive ELISA method [36, 37], in
each individual ESRD patient at the beginning and at the
end of the HD session. In this regard, it is important to note
that we had previously shown that the total plasma protein
concentration in ESRD patients increases signiﬁcantly after
the HD session due to net volume ultraﬁltration [12]. There-
fore, in this study, plasma PCO are expressed as nmol/mg
protein. Scatter diagram of plasma PCO levels in haemodia-
lyzed patients is shown in Figure 2(a). In most ESRD
patients, we observed a small increase in the plasma PCO
level after the HD procedure compared to the pre-HD value.
Diﬀerently, some ESRD patients showed the same or a
slightly lower plasma PCO level immediately after the
HD session compared to the pre-HD value. The result
of the paired Student’s t-test applied to the mean value of
plasma PCO level measured in ESRD patients pre-HD (mean
0.1239± 0.0140 nmol/mg protein) and post-HD (mean
ESRD patientsHealthy subjects
(a) (b) (c) (d) (e) (f)
Figure 1: Plasma protein carbonylation. Representative SDS-PAGE (a and d) andWestern blot with anti-DNP antibody developed with ECL
(b and e) of plasma proteins in age-matched voluntary healthy subjects (a and b) and in ﬁve representative ESRD patients onmaintenance HD
(d and e). Visualization of proteins in PVDF membrane with Ponceau Red staining (c and f).
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Figure 2: Eﬀect of a single HD session on the level of plasma PCO in ESRD patients onmaintenance HD. (a) Scatter diagram showing plasma
PCO level in individual haemodialyzed patients immediately before (white circles) and after (grey circles) a single HD session. (b) Histograms
showing the mean plasma PCO level in MHD patients immediately before (pre-HD) and after (post-HD) a single HD session. Data are
expressed as the mean ± SE. ∗p < 0 05.
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0.1332± 0.0140 nmol/mg protein) proved that the means
are signiﬁcantly diﬀerent (p < 0 05) (Figure 2(b)). There
were no diﬀerences between patients showing an increase
as compared to those showing no change or a slight decrease
in plasma carbonyl levels after dialysis. In particular, we did
not notice any diﬀerence in chronological age, HD vintage,
body mass index, WBC count and concentration of C-
reactive protein, albumin, ﬁbrinogen, haemoglobin, urea,
creatinine, sodium, potassium, calcium, phosphorus, and
ferritin (not shown).
In HD, patient’s blood is allowed to ﬂow through a ﬁlter
(the haemodialyser), whereby waste products and excess
water are removed across a semipermeable membrane sepa-
rating ﬂowing blood from the dialysate stream. The clean
blood is then returned to the haemodialysed patient’s body,
while wastes are discharged. The main determinant of the
quality of HD therapy is represented by the artiﬁcial mem-
brane packed into the haemodialyser. The HD therapy per
se, in particular the type of dialysis membrane, contributes
to the increased production of ROS in ESRD patients [38].
Indeed, typically, an HD patient’s blood is in contact with
the synthetic HD membrane for a ∼3.5 to 4 h/session and
three sessions/a week. This prolonged contact of blood with
the synthetic polymer surface results in two long-term com-
plications, namely membrane-induced oxidative stress and
membrane-induced inﬂammation, both of which contribute
to CVD development [39]. Therefore, the dialysis ﬁlter may
have a potential relevant impact on plasma PCO levels
post-HD. Sixty-two out of 69 ESRD patients recruited in
the study were dialyzed with ﬁlters made (mainly) of PAES+
PVP that diﬀer in extension and thickness (see Materials and
Methods). Therefore, we measured the plasma PCO level
immediately before and after the HD session by subdividing
those 62 ESRD patients based on the characteristics of the
ﬁlter membrane or the dialysis technique (diﬀusive versus
diﬀusive plus convective) used during the HD session. As
shown in Figures 3 and 4, the comparison of ﬁlter type
(Figure 3(a)), membrane surface area (Figure 3(b)), and
membrane thickness (Figure 3(c)) as well as dialysis tech-
nique (Figure 4) did not reveal any statistically signiﬁcant
diﬀerence in plasma PCO levels before (pre-HD) and after
(post-HD) the HD session.
Considering that diabetes mellitus occurs as an impor-
tant comorbidity in the ESRD population (often composed
predominantly of subjects in advanced age) and that some
studies suggest that oxidative stress in diabetic patients leads
to increased plasma PCO levels [40, 41], we hypothesized
that diabetic ESRD patients could experience a signiﬁcant
increased oxidative stress in comparison with nondiabetic
ESRD patients. Therefore, we evaluated the plasma PCO
levels immediately before and after a single HD session by
subdividing all ESRD patients into diabetics (n = 22; mean
age: 71.6± 2.1 yrs; HD vintage: 5.1± 0.7 yrs) and nondiabetics
(n = 47; mean age: 67.8± 2.0 yrs; HD vintage: 6.1± 0.6 years)
(Figure 5). Data were analysed according to a paired sample
t-test used to compare means of pre- and post-HD plasma
PCO level in each of the two groups of haemodialyzed
patients. The results proved that the means pre-HD and
post-HD are signiﬁcantly diﬀerent in nondiabetics (0.1172±
0.0166 nmol/mg protein and 0.1268± 0.0172 nmol/mg pro-
tein, resp., p < 0 05), whereas they are not signiﬁcantly
diﬀerent in diabetics (0.1382± 0.0264 nmol/mg protein and
0.1467± 0.0244 nmol/mg protein, resp.) (Figure 5(a)); in
addition, diﬀerences in both pre-HD and post-HD plasma
PCO levels between diabetics and nondiabetics are not statis-
tically signiﬁcant (t-test for independent samples). Pre-HD
plasma PCO levels were signiﬁcantly positively correlated
with post-HD plasma PCO concentrations both in non-
diabetic (r = 0 9766, p < 0 0001) (Figure 5(b)) and diabetic
(r = 0 9033, p < 0 0001) (Figure 5(c)) ESRD patients.
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Figure 3: Inﬂuence of the dialysis ﬁlter type on the level of plasma PCO in ESRD patients on maintenance HD. Haemodialyzed patients
(n = 62) were divided into subgroups based on the characteristics of the dialysis ﬁlters used during the HD session: (a) ﬁlter type (i.e.,
Revaclear™ 300, Revaclear 400, Polyﬂux™ 170 H, and Polyﬂux 210 H), (b) membrane surface area, and (c) membrane thickness. In all
panels, histograms show the plasma PCO level in haemodialysed patients immediately before (pre-HD, white bars) and after (post-HD,
grey bars) a single HD session. For ﬁlter details, see the Materials and Methods section. The seven remaining ESRD patients, who were
dialyzed with Filtryzer 1.6, Nephral™ ST 400, or Nephral ST 500 ﬁlters, were not included because their number is too low to make a
reliable statistical analysis. Data are expressed as the mean ± SE.
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We also evaluated the plasma PCO levels immediately
before and after a single HD session by separating ESRD
patients on HD by gender (males: n = 45, mean age 70.1±
2.4 yrs, HD vintage 5.6± 0.6 yrs; females: n = 24, mean age
66.9± 3.1 yrs; HD vintage 6.1± 0.8 yrs) (Figure 6). Data were
analysed according to a paired sample t-test used to compare
means of pre- and post-HD plasma PCO level in each of the
two groups of haemodialysed patients. The results proved
that the means pre-HD and post-HD are not signiﬁcantly
diﬀerent in males (0.1180± 0.0163 nmol/mg protein and
0.1187± 0.0134 nmol/mg protein, resp.), whereas they are
signiﬁcantly diﬀerent in females (0.1348± 0.0267 nmol/mg
protein and 0.1604±0.0313nmol/mg protein, resp., p < 0 01)
(Figure 6(a)); in addition, diﬀerences in both pre-HD and
post-HD plasma PCO levels between men and women are
not statistically signiﬁcant (unpaired t-test). Pre-HD plasma
PCO levels were signiﬁcantly positively correlated with
post-HD plasma PCO concentrations both in male (r =
0 9730, p < 0 0001) (Figure 6(b)) and female (r = 0 9702,
p < 0 0001) (Figure 5(c)) ESRD patients.
4. Discussion
Protein carbonylation, which may result from direct oxida-
tion of lysine, arginine, proline, and threonine residues and
interaction with reactive carbonyl species produced from
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Figure 4: Inﬂuence of the dialysis technique (diﬀusive versus diﬀusive plus convective) on the level of plasma PCO in ESRD patients on
maintenance HD. Haemodialyzed patients were divided into subgroups based on the dialysis technique used during the HD session: (a)
diﬀusive technique (standard bicarbonate haemodialysis) (n = 41), (b) diﬀusive plus convective techniques (online HDF) and acetate-free
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Figure 5: Plasma PCO levels measured in nondiabetic and diabetic ESRD patients on maintenance HD. (a) Histogram showing the plasma
PCO level in nondiabetic and diabetic haemodialyzed patients measured immediately before (pre-HD, white bars) and after (post-HD, grey
bars) a single HD session. Data are expressed as the mean ± SE. (b) Regression analysis showing the relation between pre-HD and post-HD
plasma PCO levels in nondiabetic haemodialyzed patients. Slope of the line is a = 1 0154. (c) Regression analysis showing the relation between
pre-HD and post-HD plasma PCO levels in diabetic haemodialyzed patients. Slope of the line is a = 0 8349. ∗p < 0 05.
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carbohydrate and lipid oxidation or non-oxidative reactions
with dicarbonyl compounds, is an indicator of oxidative pro-
tein damage [42]. Its use as a biomarker of oxidative stress
has some advantages because of the stability of PCO in com-
parison with other oxidation products. We showed that
plasma proteins of ESRD patients on HD exhibited an
increase in carbonyl content compared to plasma proteins
of the controls, which was especially evident in albumin
(Figure 1). These results are in agreement with a previous
study, which showed that post-HD plasma PCO levels are
signiﬁcantly increased compared to pre-HD levels and that
carbonylation aﬀects almost a dozen of plasma proteins,
among which albumin is the most susceptible to carbonyl
formation [24]. In this regard, it is interesting to note that
following carbonylation, albumin vasculoprotective eﬀects
in haemodialysed patients are impaired [43] and, there-
fore, carbonylated albumin may play a role in the early
atherogenic events of chronic uraemia by directly damaging
the endothelium [24].
The increased levels of PCO measured in haemodialysed
patients suggest that protein carbonylation may be an impor-
tant biomarker of oxidative stress in ESRD patients as well. A
number of studies compared biomarkers of oxidative stress
between ESRD patients and age-matched healthy subjects
[19, 28, 44] or between CKD patients with diﬀerent CKD
stages [45–47]. Here, we compared plasma levels of PCO of
each patient before and after a single HD session. We found
that mean post-HD levels of plasma PCO are signiﬁcantly
higher than mean plasma PCO levels before the HD session
(Figure 2). These results are in agreement with previous ones
showing that the levels of plasma PCO were signiﬁcantly
higher at the end of a single HD session than before it
[17–19, 24, 25, 48], whereas they diﬀer from those of a
unique study that did not report any increase in plasma
PCO level after HD [49] (Table 2).
About the possible inﬂuence of the dialysis membrane on
PCO levels, we have considered that during the HD session,
the contact of blood with the dialysis membrane and the loss
of antioxidants may promote oxidative stress. In a study con-
ducted on 15 nondiabetic ESRD patients (9 males and 6
females), PCO levels were found to be signiﬁcantly increased
after a HD session with a cuprophane membrane [50] and
increased, but not signiﬁcantly, after a HD session with a
polysulfone membrane [50]. This data is intuitive, as hydro-
philic cuprophane membranes are known to severely activate
complement and leukocytes [51]. In addition, proteomic
investigations suggest that dialysis membranes may retain,
at least in part, plasma proteins, especially carbonylated ones
[52, 53]. This would occur mainly via the protein adsorptive
properties of the membrane material [54], since the main
mechanisms for solute removal during HD, diﬀusion, and
convection have poor ability to remove high molecular
weight solutes, such as proteins. Most of haemodialysed
patients recruited into the study were dialyzed using mem-
branes made of PAES and PVP±PA that diﬀer in surface
and thickness (see Materials and Methods). In this regard,
neither dialysis membrane composition, surface, and thick-
ness (Figure 3) nor dialysis technique (Figure 4) signiﬁcantly
aﬀected pre-HD and post-HD levels of plasma PCO.
Therefore, the membrane surface area and thickness of
the dialysis ﬁlter as well as the dialysis technique do not
signiﬁcantly aﬀect the observed increase in PCO during
the HD session. It is interesting to note that some evidence
suggests a progressive signiﬁcant decrease in concentration
of inﬂammatory biomarkers [55] and advanced oxidation
protein products [56] when vitamin E-coated polysulfone
membranes are used for the dialysis sessions. This might
suggest a protective eﬀect of vitamin E-coated polysulfone
membrane against inﬂammation and oxidative stress in
haemodialysed patients.
It is well known that oxidative stress is increased in diabe-
tes mellitus. In particular, some studies have shown that
plasma PCO levels are increased in diabetics [40, 41]. Unfor-
tunately, the combination of CKD and diabetes is associated
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Figure 6: Plasma PCO levels evaluated in male and female ESRD patients onmaintenance HD. (a) Histogram showing the plasma PCO levels
in male and female ESRD patients measured immediately before (pre-HD, white bars) and after (post-HD, grey bars) a single HD session.
Data are expressed as the mean ± SE. (b) Regression analysis showing the relation between pre-HD plasma PCO levels and post-HD
plasma PCO levels in male ESRD patients. Slope of the line is a = 0 7993 (c) Regression analysis showing the relation between pre-HD
plasma PCO levels and post-HD plasma PCO levels in female ESRD patients. Slope of the line is a = 1 1383. ∗∗p < 0 01.
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with increased morbidity and mortality, mainly due to
increased cardiovascular risk [57]. About one-third (32%)
of the haemodialysed patients recruited in our study are dia-
betics. Hence, we compared plasma PCO levels before and
after a single HD session in diabetic and nondiabetic ESRD
patients (Figure 5). Unexpectedly, pre-HD PCO levels are
not signiﬁcantly diﬀerent in nondiabetic and diabetic ESRD
patients nor are the post-HD ones. Nevertheless, the mean
value of plasma PCO levels increases slightly but signiﬁcantly
in nondiabetic ESRD patients after the HD session. Diﬀer-
ently, the mean values of pre-HD and post-HD plasma
PCO levels are not signiﬁcantly diﬀerent in diabetic ESRD
patients. These ﬁndings could suggest that the HD session
induces a moderate increase in oxidative/carbonyl stress.
Therefore, nondiabetic ESRD patients seem to be more sus-
ceptible to oxidative stress induced by the HD session. These
results are only partially consistent with those described by
Dursun and colleagues [58], who determined the levels of
several biomarkers of oxidative stress in 20 nondiabetic
ESRD patients (9 males and 11 females) and 20 diabetic
ESRD patients (9 males and 11 females) before and after
HD. They concluded that both diabetes and HD increase
Table 2: Studies that examined the plasma PCO levels in haemodialysed patients before haemodialysis (pre-HD) and after haemodialysis
(post-HD).
Study
HD group
number (age and sex)
and dialysis vintage
Control group
number (age and sex)
PCO HD group
PCO
control group
Ward et al. [17]
22 HD patients
(age 51± 5 years, 8 M and 4 F).
Divided into two groups:
11 patients treated with
polysulfone membrane
11 patients treated with
cellulose triacetate membrane
Dialysis vintage 49± 11 months
17 healthy subjects
(age range 23–54 years,
both M and F)
Polysulfone membrane
pre-HD
0.144± 0.037mmol/mg
protein post-HD
0.175± 0.029mmol/mg
protein p < 0 05
Cellulose triacetate
membrane pre-HD
0.145± 0.030mmol/mg
protein post-HD
0.178± 0.035mmol/mg
protein p < 0 05
0.041± 0.008
mmol/mg protein
Dursun et al. [48]
20 HD patients
(age and sex unspeciﬁed)
Dialysis vintage unspeciﬁed
20 healthy subjects
(age and sex unspeciﬁed)
Pre-HD
0.889± 0.063 nmol/mg
protein post-HD
0.997± 0.066 nmol/mg
protein p < 0 05
0.417± 0.036
nmol/mg protein
Pieniazek et al. [18]
10 HD patients
(mean age 58± 11 years,
sex unspeciﬁed)
Dialysis vintage unspeciﬁed
9 healthy subjects
(age 46 ± 15 years,
sex unspeciﬁed)
Pre-HD
2.27± 0.2mmol/l
post-HD
2.94± 0.12mmol/l
p < 0 0002
0.67± 0.07mmol/l
Terawaki et al. [49]
83 anuric HD patients
divided into two groups:
patients with CVD
(n = 66, age 63.5± 12.5 years,
32 M and 34 F)
Dialysis vintage 85.0± 64.6 months
patients without CVD
(n = 20, age 74.3± 12.8 years,
11 M and 9 F)
Dialysis vintage 58.3± 33.3 months
—
patients with CVD
pre-HD
0.81± 0.16 nmol/mg
protein post-HD
0.53± 0.13 nmol/mg protein
patients without CVD
pre-HD
0.82± 0.17 nmol/mg protein
post-HD
0.58± 0.16 nmol/mg protein
—
Albarello et al. [25]
23 HD patients
(9 men and 14 women,
mean age 50.8± 17.3 years)
Dialysis vintage unspeciﬁed
—
Pre-HD
0.62± 0.14 nmol/mg protein
post-HD
0.86± 0.16 nmol/mg protein
p < 0 001
—
Caimi et al. [19]
31 HD patients
(61.5± 12.8 years, 16 men
and 15 women)
Dialysis vintage 48.5± 35.7 months
26 healthy subjects
(age 43.54± 6.92 years,
17 M and 9 F)
Pre-HD
0.62± 0.14 nmol/mg protein
post-HD
0.86± 0.16 nmol/mg protein
p < 0 01
0.440± 0.134
nmol/mg protein
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oxidative stress and that their combined eﬀect on oxidative
stress is greatest in diabetic ESRD patients. However, a limi-
tation of their study was the very small number of subjects.
In contrast to what is observed in the general population,
where females have a longer life expectancy than males [59],
female ESRD patients have as poor survival as male ESRD
patients [60, 61]. These observations are somewhat surpris-
ing considering that haemodialysed women have a lower
prevalence of CVD [62] are less likely to develop left-
ventricular hypertrophy [63] and are less predisposed to
cardiovascular calciﬁcation [64]. It has been suggested that
noncardiovascular mortality is the main explanation for the
loss of the survival advantage in ESRD women on HD [62].
Moreover, the HD procedure too may contribute to cancel
out the survival advantage in ESRD women [60]. So, we com-
pared plasma PCO levels before and after a single HD session
in male and female ESRD patients (Figure 6). In men, the
mean values of pre-HD and post-HD plasma PCO levels
are not signiﬁcantly diﬀerent, whereas in women, the mean
value of post-HD plasma PCO level is signiﬁcantly higher
than that of pre-HD. These novel ﬁndings suggest that hae-
modialysed women seem to be more susceptible to oxidative
stress induced by the HD session.
In summary, all these results suggest that (i) the HD ses-
sion increases plasma protein carbonylation; therefore,
although important advances have been done in the ﬁeld of
dialysis biocompatibility, the HD session probably still repre-
sents a source of oxidative stress; (ii) plasma PCO level mea-
surement may become an indicator of oxidative/carbonyl
stress in ESRD and could be included in the routine monitor-
ing of haemodialysed patients, since standard uraemia and
inﬂammation biomarkers may not be suﬃcient on their
own to describe the inﬂammatory/oxidative state of ESRD
patients on HD; and (iii) haemodialysed women seem to be
more susceptible to oxidative/carbonyl stress induced by
the HD session than men. On the basis of these ﬁndings, it
seems appropriate to suggest that the female sex could be
considered a fundamental biologic variable (or a “risk fac-
tor”) associated with HD-induced plasma protein carbonyla-
tion in ESRD patients on maintenance HD. Therefore, this
study shows that gender diﬀerences exist in plasma PCO
levels of haemodialysed patients before and after a single
HD session and highlights the critical importance of report-
ing of sex information in study description, data analyses,
results, and their interpretation in basic science and medi-
cal/clinical research studies concerning ESRD. As a matter
of fact, the prevalence of CKD stages 1–5 among US adults
aged 18 years or older is higher in women than men (16%
versus 13%); however, men are 64% more likely than women
to develop ESRD [65], yet most studies of ESRD group
together men and women and assume any underlying patho-
physiology is the same. So, this study can contribute, in its
own small way, to increase our understanding of the gender
diﬀerences of diseases, in particular in the ﬁeld of nephrol-
ogy, where some gender diﬀerences have been documented
[66]. Indeed, women seem to be somewhat protected from
developing ESRD [67]. In addition, the cumulative incidence
of ESRD is low during the reproductive ages and begins to
rise ten years later in women than in men among participants
in community-based screenings. Moreover, the mean age at
the start of HD is also higher in women than in men [67].
Finally, our study has some limitations. Firstly, it includes
a relatively small number of ESRD male and female patients
and has been performed in only one single HD center.
Secondly, the majority of the patients studied in this cohort
are from Italy and of Caucasian race, and the applicability
of the study ﬁndings across nationalities and races remains
unclear. However, we hope that these results stimulate fur-
ther research with a larger number of men and women on
HD recruited from diﬀerent dialysis centers, possibly of dif-
ferent nationalities and races, to advance our understanding
of the pathophysiology of sex (and possibly of nationality
and/or race) diﬀerences in CKD and improve clinical care
of women with CKD. While some advances have been made
in both clinical and basic research, much remains poorly
understood, both at the molecular and clinical levels.
5. Conclusions
Post-HD plasma PCO level increases in nondiabetic but not
in diabetic ESRD patients, more markedly in women than
in men. Women with ESRD are more susceptible than men
to HD-induced oxidative/carbonyl stress.
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